English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Venous Thromboembolism (VTE) includes both Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE) and can range from asymptomatic to fatal. It is a common medical condition annually affecting at least 9,00,000 individuals in the United States [1]. Mortality for untreated PE is approximately 30%, which can decrease to 2-8% with adequate treatment. In 2008, according to the Centers for Disease Control and Prevention, VTE caused more deaths than breast cancer, human immunodeficiency virus, and traffic accidents combined. It has been estimated that up to 100,000 people die each year from VTE [1]. Given its high mortality, patients with VTE are frequently admitted to the hospital for initiation of anticoagulation therapy. However, there has been increasing evidence to support treat-and-release of VTE patients who are at low risk of recurrence or bleeding and can be safely managed in the outpatient setting [2,3].

Patterns of Discharge Disposition among Patients Diagnosed with Venous Thromboembolism in the Emergency Department: A Multicenter Retrospective Cohort Evaluation